Since antibiotics were first discovered, bacteria have been evolving to outsmart them. But today, the latest science is rising up to meet the challenge. This season of Science Will Win is exploring how artificial intelligence (AI) can help the scientific community overcome one of the greatest challenges facing humanity: antimicrobial resistance. This season, we’ll hear from researchers, doctors, patients, patient advocates, computer scientists, and AI experts. All of them are on the cutting edge of the fight against antimicrobial resistance. Tune in to this new, four-part series, coming soon!

Season 3 of Science Will Win is created by Pfizer and hosted by Jeremiah Owyang, entrepreneur, investor, and tech industry analyst. It’s produced by Wonder Media Network.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In part two of this series, Adam Rutherford and guests break down the next step in how potential breast cancer treatments move forward from the lab. What role do clinical trials play in the development of potential treatments? How are clinical trials developed? How can patients access clinical trials? And how are researchers and advocacy groups working to break down barriers in access to clinical trials?

Featured Guests:

• Laurie, Breast Cancer Clinical Trial Participant
• Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
• Julia Perkins Smith, Global Clinical Lead, Pfizer
• Jamil Rivers, CEO, Chrysalis Initiative

Additional Resources:

• pfizerclinicaltrials.com/oncology
• pfizerclinicaltrials.com
• pfizerestudiosclinicos.com

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Oncologists have more innovative methods for treating breast cancer than ever before. In part one of this two-part series, Adam Rutherford and guests explore the hurdles and successes researchers face as they work to develop new, targeted therapies for breast cancer.

Featured Guests:

• Martha Carlson, Breast Cancer Advocate & Writer
• Dr. Edith Mitchell, Medical Oncologist, Thomas Jefferson University
• Jeff Settleman, Chief Scientific Officer, Pfizer Oncology

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Host Adam Rutherford returns to explore breakthroughs in oncology, the study and treatment of cancer, and more specifically breast cancer. We’ll hear from the scientists tasked with developing new treatments, oncologists who lead clinical trials and treat patients, and the patients and patient advocates themselves. It’s a groundbreaking time for cancer research, with as many promising possibilities as there are challenges to overcome. Tune in to this new, two-part series, launching October 27, 2022!

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special bonus episode, Adam Rutherford explores a different aspect of gene therapy - how do you actually make one? Expert guests discuss the highly complex task of scaling-up manufacturing from the small amounts needed for research, to creating batches big enough for clinical and commercial scale. And once that hurdle has been cleared, how do they address the additional challenge of storing and transporting the medicine at ultra-low temperatures?

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer
Bob Smith, Senior Vice President, Global Gene Therapy Business, Rare Disease, Pfizer 
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gene therapy is at a pivotal moment. For eligible rare disease patients, the potential impact could be huge. So how can we support that potential to fruition and what will it mean if we do? In our season finale, host Adam Rutherford and guests take a peek into what a world with successful gene therapies could look like for patients, healthcare and society.

Featuring guests:
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Former Senior Project Manager, EURORDIS
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Paige Bischoff, Senior Vice President, Global Public Affairs,  Alliance for Regenerative Medicine
Paolo Morgese, EU Director, Market Access, Alliance for Regenerative Medicine
Reda Guiha, IDM Regional President, Rare Disease, Pfizer
Simone Boselli, Director, Public Affairs, EURORDIS
Tomislav Sokol, Member of European Parliament

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As with any new breakthrough medicine, entering the healthcare system comes with a host of obstacles and potential barriers. In this episode, Adam Rutherford and guests break down the big changes needed within the global healthcare ecosystem to ensure that, once approved, the therapies we’re researching now, like gene therapy, reach the patients who need them.

Featuring guests:
Bert Bruce, Regional President, North America, Rare Disease, Pfizer 
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Karolina Hanslik, Senior Project Manager, EURORDIS
Katherine Beaverson, Senior Director and Patient Advocacy Lead, Rare Disease Research Unit, Pfizer
Nikhil Gadre, Senior Director, Global Commercial, Hemophilia Gene Therapy, Pfizer
Suneet Varma, Global President, Rare Disease, Pfizer
Tomislav Sokol, Member of European Parliament



 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gene therapy has come a long way to get where it is today but there is still much to learn and investigate. Host Adam Rutherford speaks to a line-up of experts about the vital role of clinical trials and the unique challenges facing gene therapy and rare disease patients.

Featuring guests:
Brenda Cooperstone, Senior Vice President, Chief Development Officer, Rare Disease, Pfizer
Emily Crossley, Chief Executive Officer, Duchenne UK
Erik Paulsen, Chair, Institute for Gene Therapies
Professor John Rasko, Clinical Haematologist & Trial Investigator, University of Sydney
Simone Boselli, Director, Public Affairs, EURORDIS
Suneet Varma, Global President, Rare Disease, Pfizer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Gene therapy is a revolutionary field of science that has the potential to transform lives. It presents this big question; What if we could treat a disease at its root cause, rather than just the symptoms? On the first episode of Science Will Win, host Adam Rutherford takes us through the history, science, and significance of gene therapy.

Featuring guests:

Dirk Vander Mijnsbrugge, Vice President, Medical Affairs, Rare Diseases, Pfizer
Durhane Wong-Rieger, President & CEO at Canadian Organization for Rare Disorders
Laurence Woollard, Director, On The Pulse Consultancy
Sonal Bhatia, Chief Medical Officer, Rare Disease, Pfizer

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. 

Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. 

At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.